It is what is going to happen to the sales force, this is a dead company walking folks.
This company was modeled to learn from the failures of Reliant and to move forward, but several things make this company dead in the water.
1. No Large Pharma Company Bought Amarin - Amarin didn't want to launch Vascepa, they wanted to sell it to another company to launch, once that didn't happen, that was a bad sign because Amarin would have to finance this launch.
2. Generic LOVAZA - Generic LOVAZA is probably going to be on the market in Q1 or Q2 of next year. Once that happens, good night Vascepa, no Managed Care Company is going to approve LOVAZA or VASCEPA once a generic is available.
3. Too Much Money Spent - Amarin spent too much on buying speakers and using the coupons. Unfortunately, most of the coupons are being used on Medicare and being processed as cash pay and are costing the company 3x more than budgeted. Also, paying the amount of money to speakers is draining the budget.
4. REDUCE IT - this was the nail in the coffin! Not completed until 2016/2017 and costings $100s millions of dollars is not going to happen without a company purchasing Amarin or a big time investor, which isn't going to come with Generic LOVAZA on the Market.
Be smart folks, nobody has tenure at Amarin and you will get 2 weeks and be let go! Trust me, I know this, I know the people at Amarin making the decisions....I know who these individuals have reached out to discuss what happens next....BE SMART!
This company was modeled to learn from the failures of Reliant and to move forward, but several things make this company dead in the water.
1. No Large Pharma Company Bought Amarin - Amarin didn't want to launch Vascepa, they wanted to sell it to another company to launch, once that didn't happen, that was a bad sign because Amarin would have to finance this launch.
2. Generic LOVAZA - Generic LOVAZA is probably going to be on the market in Q1 or Q2 of next year. Once that happens, good night Vascepa, no Managed Care Company is going to approve LOVAZA or VASCEPA once a generic is available.
3. Too Much Money Spent - Amarin spent too much on buying speakers and using the coupons. Unfortunately, most of the coupons are being used on Medicare and being processed as cash pay and are costing the company 3x more than budgeted. Also, paying the amount of money to speakers is draining the budget.
4. REDUCE IT - this was the nail in the coffin! Not completed until 2016/2017 and costings $100s millions of dollars is not going to happen without a company purchasing Amarin or a big time investor, which isn't going to come with Generic LOVAZA on the Market.
Be smart folks, nobody has tenure at Amarin and you will get 2 weeks and be let go! Trust me, I know this, I know the people at Amarin making the decisions....I know who these individuals have reached out to discuss what happens next....BE SMART!